Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 8/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30597321 | 1.00 | NOS2 (0.44) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL25410996 | 0.89 | NOS2 (0.50) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL26317972 | 0.82 | NOS2 (0.42) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL25413286 | 0.82 | NOS2 (0.46) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL25413093 | 0.82 | NOS2 (0.52) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL31671090 | 0.82 | NOS2 (0.52) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL25413948 | 0.81 | NOS2 (0.47) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL30597289 | 0.79 | KDM4E (0.43) | ALDH1A1 | |
| SCHEMBL25412080 | 0.79 | KDM4E (0.43) | ALDH1A1 | |
| SCHEMBL25411850 | 0.78 | KDM4E (0.39) | ALDH1A1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | Gacter Inc. (US) | 2023-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286913-A1 | INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF | NOS1, NOS3, NOS2 | NOS2 3/4885CYP2D6 360/4885SLC6A2 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.